MCIC Repost:
SUN VALLEY, CA, Jan 21, 2016 (Marketwired via COMTEX) -- MultiCorp International, Inc. (otc pink:MCIC) has received a report from the U.S. Food and Drug Administration that gives the company specific guidelines in creating a 4 arm study to administer the patented migraine medicine in an emergency room setting.
The company released the following statement: "The company has received a detailed response to the Pre-IND submission sent to the U.S. Food and Drug Administration for the further development of the patented migraine medicine the company has ownership in. The FDA has responded in supplying the company with a clear roadmap to develop a 4 arm study wherein the medicine will be dispensed in an emergency room setting for patients that enter the ER for migraine relief. This study will give the company feedback on the efficacy of the drug as compared to other medications currently being dispensed to relieve migraines. This study significantly will speed up the process to bring the product to market."
The company also stated it is suspending all other areas of business to focus 100% on the further development of the medicine. As the migraine industry in the U.S. is currently in excess of $800 Million per year, the company feels that this medicine could capture a 10-15% market share which would place a value of the medicine at $80-$120 Million.
